Status:
COMPLETED
Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.
Detailed Description
This is a single dose, randomised, double-blind, double-dummy, 3 period cross-over, placebo controlled, multinational, multicentre trial.
Eligibility Criteria
Inclusion
- Males and females aged ≥ 40 years
- Current or ex-smokers of ≥ 10 pack-year
- Clinical diagnosis of severe stable COPD
Exclusion
- History or current diagnosis of asthma, allergic rhinitis, or atopy
- Respiratory tract infection or acute COPD exacerbation in the last 6 weeks
- Hospitalised for an acute COPD exacerbation in the last 3 months
- Evidence of contraindicated use of anticholinergic drugs
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00435760
Start Date
February 1 2007
End Date
August 1 2007
Last Update
November 17 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Respiratory Clinical Trials Ltd
London, United Kingdom, W1G 8HU